Join Growin Stock Community!

Allogene therapeutics, inc.ALLO.US Overview

US StockHealthcare
(No presentation for ALLO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALLO AI Insights

ALLO Overall Performance

ALLO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALLO Recent Performance

-6.12%

Allogene therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ALLO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALLO Key Information

ALLO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALLO Profile

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Price of ALLO

ALLO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALLO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11631.14
PB Ratio
1.95
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1170863.64%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11631.14
PB Ratio
1.95
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1170863.64%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ALLO's latest earnings report released?

    The most recent financial report for Allogene therapeutics, inc. (ALLO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALLO's short-term business performance and financial health. For the latest updates on ALLO's earnings releases, visit this page regularly.

  • How much cash does ALLO have?

    At the end of the period, Allogene therapeutics, inc. (ALLO) held Total Cash and Cash Equivalents of 48.11M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ALLO's EPS continuing to grow?

    According to the past four quarterly reports, Allogene therapeutics, inc. (ALLO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALLO?

    Allogene therapeutics, inc. (ALLO)'s Free Cash Flow (FCF) for the period is -29.93M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 32.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ALLO?

    The latest valuation data shows Allogene therapeutics, inc. (ALLO) has a Price-To-Earnings (PE) ratio of -1.11 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.